The NHS will offer a new personalised CAR-T immunotherapy, obe-cel (Aucatzyl; obecabtagene autoleucel), to adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (B-cell ALL) after positive clinical results and regulatory approval. The treatment, which reprogrammes a patient’s own T cells in the lab and returns them as a living medicine, was approved by NICE and given interim funding via the Cancer Drugs Fund to speed rollout through specialist CAR-T centres.
Eligibility and scale
The therapy will be available to adults aged 26 and over with relapsed or treatment-resistant B-cell ALL. NHS England estimates roughly 50 people a year in England could be eligible, and the number of centres offering obe-cel is planned to grow through 2026 and 2027.
Clinical outcomes and safety
In trials, 77% of participants treated with obe-cel went into remission, and about half of those patients had no detectable disease after three and a half years. On average the therapy extended survival by 15.6 months. Compared with other CAR-T products, obe-cel showed lower toxicity and a reduced chance of severe side effects. Reported adverse events were generally mild to moderate; the most common was Cytokine Release Syndrome (CRS), an immune reaction that causes flu-like symptoms.
Administration
Patients receive two intravenous doses, given ten days apart, at designated specialist centres. Developers and clinicians note obe-cel was designed with potential for outpatient delivery, which could improve access for older patients or those with other health conditions and might eventually allow treatment closer to home.
Voices and reaction
NHS clinical leaders said the therapy could extend cancer-free survival and, for some people, offer the hope of a cure. A patient treated in a 2024 trial described results that exceeded expectations and fewer severe side effects, and welcomed its NHS availability for adults. Health ministers and NHS representatives framed the approval as an example of collaboration between the NHS and the UK life sciences sector in bringing innovative treatments into routine care.
Researchers, clinicians and patient groups also praised the move. Contributors highlighted the UK-based development pathway from university research to an NHS-delivered product and said wider availability will let more patients benefit from CAR-T options for blood cancers.
Manufacturing and context
Aucatzyl is produced by Autolus Therapeutics, a spin-out from University College London, with manufacture in Stevenage, a UK hub for cell and gene therapy companies. Acute lymphoblastic leukaemia is an aggressive blood and bone marrow cancer; around 800 people in the UK are diagnosed each year, about half of them adults. For aggressive cases treated with standard chemotherapy, median survival is roughly 10 months. The NHS began offering CAR-T therapies in 2018 and has since expanded its portfolio for adult and paediatric blood cancers. Clinical trials for obe-cel were run at multiple NHS hospitals across the UK.